Product Name:Diethyl 3,5-dimethyl-1H-pyrrole-2,4-dicarboxylate

IUPAC Name:2,4-diethyl 3,5-dimethyl-1H-pyrrole-2,4-dicarboxylate

CAS:2436-79-5
Molecular Formula:C12H17NO4
Purity:95%+
Catalog Number:CM197337
Molecular Weight:239.27

Packing Unit Available Stock Price($) Quantity
CM197337-100g in stock ȋǺȋ
CM197337-500g in stock œdžǺ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:2436-79-5
Molecular Formula:C12H17NO4
Melting Point:-
Smiles Code:O=C(C1=C(C)C(C(OCC)=O)=C(C)N1)OCC
Density:
Catalog Number:CM197337
Molecular Weight:239.27
Boiling Point:372.3°C at 760 mmHg
MDL No:MFCD00005218
Storage:Store at room temperature.

Category Infos

Pyrroles
Pyrrole is a five membered heterocyclic compound with the molecular formula of C4H5N. Pyrrole has a ring composed of four carbon atoms and one nitrogen atom. Pyrrole is easy to polymerize in the air. Pyrrole is the parent compound of many important biological substances (such as bile pigment, porphyrin and chlorophyll). Pyrrole scaffolds are widely used in biological and pharmaceutical fields. Pyrrole is a special heterocyclic scaffold, which exists in many natural products, drug molecules and pesticides, and has shown its application in materials science.
Pyrrole,Where to Buy Pyrroles-Chemenu
Pyrrole,Where to Buy Pyrroles
Pyrrole is a heterocyclic, aromatic, organic compound, a five-membered ring with the formula C 4H 4NH. It is a colorless volatile liquid that darkens readily upon exposure to air. Substituted derivatives are also called pyrroles, e.g., N-methylpyrrole.

Column Infos

Vorolanib
EyePoint Pharmaceuticals announced on December 4th announced positive topline results of its Phase 2 DAVIO 2 trial of EYP-1901, an investigational sustained delivery maintenance treatment for wet age-related macular degeneration (wet AMD) combining vorolanib, a selective tyrosine kinase inhibitor with bioerodible Durasert E™. Vorolanib brings a new mechanistic approach to the treatment of VEGF-mediated retinal diseases as a pan-VEGF receptor blocker, blocking all VEGF isoforms. Vorolanib features reduced off-target binding and at clinically relevant doses does not inhibit Tie-2, a critical pathway associated with vascular stability, which may result in an improved efficacy. Further, in an in-vivo model of retinal detachment, vorolanib demonstrated neuroprotection, and potential antifibrotic benefits.

Related Products